Management of opioid use disorders: A national clinical practice guideline

CMAJ

Volumn 190, Issue 9, 2018, Pages E247-E257

  Bruneau, Julie ^a,b   Ahamad, Keith ^c   Goyer, Marie Ève ^b,d   Poulin, Ginette ^e,f   Selby, Peter ^g,h   Fischer, Benedikt ^g,h   Wild, T Cameron ⁱ   Wood, Evan ^c  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d Centre Intégré Universitaire de Santé et de Services Sociaux de l'Est de l Île de Montréal Hôpital   (Canada)

^e UNIVERSITY OF MANITOBA   (Canada)

^f UNIVERSITY OF MANITOBA   (Canada)

^g CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^h UNIVERSITY OF TORONTO   (Canada)

ⁱ UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BUPRENORPHINE PLUS NALOXONE; METHADONE; MORPHINE; OPIATE AGONIST; OPIATE ANTAGONIST; NARCOTIC ANALGESIC AGENT;

ARTICLE; CANADA; DRUG WITHDRAWAL; EVIDENCE BASED PRACTICE; HARM REDUCTION; HUMAN; MORTALITY RISK; OPIATE ADDICTION; PATIENT CARE; PATIENT SAFETY; PRACTICE GUIDELINE; PSYCHOSOCIAL CARE; PUBLIC HEALTH SERVICE; RELAPSE; DRUG OVERDOSE; MEDICAL SOCIETY; PSYCHOTHERAPY; VULNERABLE POPULATION;

ANALGESICS, OPIOID; BUPRENORPHINE, NALOXONE DRUG COMBINATION; CANADA; DRUG OVERDOSE; HUMANS; OPIOID-RELATED DISORDERS; PSYCHOTHERAPY; SOCIETIES, MEDICAL; VULNERABLE POPULATIONS;

EID: 85045097726     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.170958     Document Type: Article

References (90)

1. Fairbairn N, Cofin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: challenges and innovations responding to a dynamic epidemic. Int J Drug Policy 2017;46:172-9.
2. Canadian Institute for Health Information, Canadian Centre on Substance Abuse. Hospitalizations and emergency department visits due to opioid poisoning in Canada. Ottawa: Canadian Institute for Health Information; 2016.
3. Bruneau J, Roy E, Arruda N, et al. The rising prevalence of prescription opioid injection and its association with hepatitis C incidence among street-drug users. Addiction 2012;107:1318-27.
4. Hadland SE, DeBeck K, Kerr T, et al. Prescription opioid injection and risk of hepatitis C in relation to traditional drugs of misuse in a prospective cohort of street youth. BMJ Open 2014;4:e005419.
5. Lankenau SE, Kecojevic A, Silva K. Associations between prescription opioid injection and hepatitis C virus among young injection drug users. Drugs (Abingdon Engl) 2015;22:35-42.
6. Puzhko S, Roy E, Jutras-Aswad D, et al. High hepatitis C incidence in relation to prescription opioid injection and poly-drug use: assessing barriers to hepatitis C prevention. Int J Drug Policy 2017;47:61-8.
7. Hennink M, Abbas Z, Choudhri Y, et al. Risk behaviours for infection with HIV and hepatitis C virus among people who inject drugs in Regina, Saskatchewan. Can Commun Dis Rep 2007;33:53-9.
8. Special Advisory Committee on the Epidemic of Opioid Overdoses. National report: Apparent opioid-related deaths in Canada (January 2016 to June 2017) Ottawa: Public Health Agency of Canada; 2017. Available: www.canada.ca/en/public-health/services/publications/healthy-living/apparent-opioid-related-deaths-report-2016-2017-december.html (accessed 2018 Feb. 20).
9. A province-by-province look at opioid-overdose stats, including fentanyl. Global News. 2016 Nov. 17. Available: http://globalnews.ca/news/3072316/a-province-by-province-look-at-opioid-overdose-stats-including-fentanyl (accessed 2017 Mar. 9).
10. Eibl JK, Morin K, Leinonen E, et al. The state of opioid agonist therapy in Canada 20 years afer federal oversight. Can J Psychiatry 2017;62:444-50.
11. Andrews JC, Schunemann HJ, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol 2013;66:726-35.
12. Alonso-Coello P, Oxman AD, Moberg J, et al. GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 2: Clinical practice guidelines. BMJ 2016;353:i2089.
13. Guyatt GH, Oxman AD, Kunz R, et al. GRADE: going from evidence to recommendations. BMJ 2008;336:1049-51.
14. Guyatt GH, Oxman AD, Kunz R, et al. What is "quality of evidence" and why is it important to clinicians? BMJ 2008;336:995-8.
15. Schünemann HJ, Al-Ansary LA, Forland F, et al. Guidelines International Network: principles for disclosure of interests and management of conflicts in guidelines. Ann Intern Med 2015;163:548-53.
16. Auriacombe M, Franques P, Tignol J. Deaths attributable to methadone vs. buprenorphine in France. JAMA 2001;285:45.
17. Luty J, O'Gara C, Sessay M. Is methadone too dangerous for opiate addiction? The case for using a safer alternative, buprenorphine, is strong. BMJ 2005;331: 1352-3.
18. Mattick RP, Breen C, Kimber J, et al. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev 2014;(2):CD002207.
19. Marteau D, McDonald R, Patel K. The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales. BMJ Open 2015;5:e007629.
20. Pierce M, Bird SM, Hickman M, et al. Impact of treatment for opioid dependence on fatal drug-related poisoning: a national cohort study in England. Addiction 2016;111:298-308.
21. Nielsen S, Larance B, Degenhardt L, et al. Opioid agonist treatment for pharmaceutical opioid dependent people. Cochrane Database Syst Rev 2016;(5): CD011117.
22. Maremmani I, Gerra G. Buprenorphine-based regimens and methadone for the medical management of opioid dependence: selecting the appropriate drug for treatment. Am J Addict 2010;19:557-68.
23. Bonhomme J, Shim RS, Gooden R, et al. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc 2012;104:342-50.
24. Dasgupta N, Bailey EJ, Cicero T, et al. Post-marketing surveillance of methadone and buprenorphine in the United States. Pain Med 2010;11:1078-91.
25. Bell JR, Butler B, Lawrance A, et al. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009; 104:73-7.
26. Maxwell JC, McCance-Katz EF. Indicators of buprenorphine and methadone use and abuse: What do we know? Am J Addict 2010;19:73-88.
27. Lofwall MR, Walsh SL. A review of buprenorphine diversion and misuse: the current evidence base and experiences from around the world. J Addict Med 2014;8:315-26.
28. D'Onofrio G, O'Connor PG, Pantalon MV, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA 2015;313:1636-44.
29. Liebschutz JM, Crooks D, Herman D, et al. Buprenorphine treatment for hospitalized, opioid-dependent patients: a randomized clinical trial. JAMA Intern Med 2014;174:1369-76.
30. Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine consensus panel on the use of buprenorphine in ofice-based treatment of opioid addiction. J Addict Med 2011;5:254-63.
31. Moody DE. Metabolic and toxicological considerations of the opioid replacement therapy and analgesic drugs: methadone and buprenorphine. Expert Opin Drug Metab Toxicol 2013;9:675-97.
32. Holland R, Maskrey V, Swif L, et al. Treatment retention, drug use and social functioning outcomes in those receiving 3 months versus 1 month of supervised opioid maintenance treatment. Results from the Super C randomized controlled trial. Addiction 2014;109:596-607.
33. Lee JD, Vocci F, Fiellin DA. Unobserved "home" induction onto buprenorphine. J Addict Med 2014;8:299-308.
34. Baser O, Chalk M, Fiellin DA, et al. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care 2011;17(SUPPL. 8):S235-48.
35. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009;104:982-92.
36. Baxter LE Sr, Campbell A, Deshields M, et al. Safe methadone induction and stabilization: report of an expert panel. J Addict Med 2013;7:377-86.
37. Fullerton CA, Kim M, Thomas CP, et al. Medication-assisted treatment with methadone: assessing the evidence. Psychiatr Serv 2014;65:146-57.
38. Thomas CP, Fullerton CA, Kim M, et al. Medication-assisted treatment with buprenorphine: assessing the evidence. Psychiatr Serv 2014;65:158-70.
39. Degenhardt L, Bucello C, Mathers B, et al. Mortality among regular or dependent users of heroin and other opioids: a systematic review and meta-analysis of cohort studies. Addiction 2011;106:32-51.
40. Mattick RP, Breen C, Kimber J, et al. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev 2009;(3):CD002209.
41. Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and afer opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ 2017;357:j1550.
42. Gladstone EJ, Smolina K, Morgan SG. Trends and sex diferences in prescription opioid deaths in British Columbia, Canada. Inj Prev 2016;22:288-90.
43. Tjagvad C, Skurtveit S, Linnet K, et al. Methadone-related overdose deaths in a liberal opioid maintenance treatment programme. Eur Addict Res 2016;22: 249-58.
44. McCance-Katz EF, Sullivan LE, Nallani S. Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review. Am J Addict 2010;19:4-16.
45. McCance-Katz EF, Rainey PM, Smith P, et al. Drug interactions between opioids and antiretroviral medications: interaction between methadone, LAAM, and delavirdine. Am J Addict 2006;15:23-34.
46. Fareed A, Patil D, Scheinberg K, et al. Comparison of QTc interval prolongation for patients in methadone versus buprenorphine maintenance treatment: a 5-year follow-up. J Addict Dis 2013;32:244-51.
47. Alinejad S, Kazemi T, Zamani N, et al. A systematic review of the cardiotoxicity of methadone. EXCLI J 2015;14:577-600.
48. Krantz MJ, Garcia JA, Mehler PS. Efects of buprenorphine on cardiac repolarization in a patient with methadone-related torsade de pointes. Pharmacotherapy 2005;25:611-4.
49. Thanavaro KL, Thanavaro JL. Methadone-induced torsades de pointes: a twist of fate. Heart Lung 2011;40:448-53.
50. Hallinan R, Byrne A, Agho K, et al. Hypogonadism in men receiving methadone and buprenorphine maintenance treatment. Int J Androl 2009;32:131-9.
51. Merza Z. Chronic use of opioids and the endocrine system. Horm Metab Res 2010;42:621-6.
52. Yee A, Loh HS, Hisham Hashim HM, et al. Clinical factors associated with sexual dysfunction among men in methadone maintenance treatment and buprenorphine maintenance treatment: a meta-analysis study. Int J Impot Res 2014;26: 161-6.
53. Amass L, Kamien JB, Mikulich SK. Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans. Drug Alcohol Depend 2001;61:173-81.
54. Marsch LA, Moore SK, Borodovsky JT, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction 2016;111:1406-15.
55. Rosado J, Walsh SL, Bigelow GE, et al. Sublingual buprenorphine/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone. Drug Alcohol Depend 2007;90:261-9.
56. Kakko J, Gronbladh L, Svanborg KD, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry 2007;164: 797-803.
57. Mannelli P, Peindl KS, Lee T, et al. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev 2012;5:52-63.
58. Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction. Treatment improvement protocol (TIP) Series 40. DHHS Publication No. (SMA) 04-3939. Rockville (MD): Substance Abuse and Mental Health Services Administration; 2004.
59. Ferri M, Minozzi S, Bo A, et al. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev 2013;(6): CD009879.
60. Beck T, Haasen C, Verthein U, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction 2014;109:617-26.
61. Falcato L, Beck T, Reimer J, et al. Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone: a randomized, crossover clinical trial. J Clin Psychopharmacol 2015;35:150-7.
62. Verthein U, Beck T, Haasen C, et al. Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res 2015;21:97-104.
63. Hämmig R, Kohler W, Bonorden-Kleij K, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat 2014;47:275-81.
64. New Information: Change of listing status of Kadian - open benefit to limited use. Non-Insured Health Benefits Program Newsletter 2014 Fall. Available: http://health.chiefs-of-ontario.org/sites/default/files/files/Health-Canada-NIHB-Pharmacy-Newsletter-Fall-2014.pdf (accessed 2017 Mar. 10).
65. Jegu J, Gallini A, Soler P, et al. Slow-release oral morphine for opioid maintenance treatment: a systematic review. Br J Clin Pharmacol 2011;71:832-43.
66. Tuten M, DeFulio A, Jones HE, et al. Abstinence-contingent recovery housing and reinforcement-based treatment following opioid detoxification. Addiction 2012;107:973-82.
67. Luty J. What works in drug addiction? Adv Psychiatr Treat 2003;9:280-8.
68. Strang J, McCambridge J, Best D, et al. Loss of tolerance and overdose mortality afer inpatient opiate detoxification: follow up study. BMJ 2003;326:959-60.
69. Amato L, Davoli M, Minozzi S, et al. Methadone at tapered doses for the management of opioid withdrawal. Cochrane Database Syst Rev 2013;(2):CD003409.
70. Gowing L, Farrell M, Ali R, et al. Alpha(2)-adrenergic agonists for the management of opioid withdrawal. Cochrane Database Syst Rev 2016;(5):CD002024.
71. Gowing L, Ali R, White JM, et al. Buprenorphine for managing opioid withdrawal. Cochrane Database Syst Rev 2017;(2):CD002025.
72. Minozzi S, Amato L, Vecchi S, et al. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev 2011;(4):CD001333.
73. Amato L, Minozzi S, Davoli M, et al. Psychosocial combined with agonist maintenance treatments versus agonist maintenance treatments alone for treatment of opioid dependence. Cochrane Database Syst Rev 2011;(10):CD004147.
74. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fifh edition. Arlington (VA): American Psychiatric Association Publishing; 2013.
75. Minozzi S, Amato L, Bellisario C, et al. Maintenance agonist treatments for opiate-dependent pregnant women. Cochrane Database Syst Rev 2013;(12):CD006318.
76. Jones HE, Martin PR, Heil SH, et al. Treatment of opioid-dependent pregnant women: clinical and research issues. J Subst Abuse Treat 2008;35:245-59.
77. Lund IO, Fitzsimons H, Tuten M, et al. Comparing methadone and buprenorphine maintenance with methadone-assisted withdrawal for the treatment of opioid dependence during pregnancy: maternal and neonatal outcomes. Subst Abuse Rehabil 2012;3(SUPPL. 1):17-25.
78. Zedler BK, Mann AL, Kim MM, et al. Buprenorphine compared with methadone to treat pregnant women with opioid use disorder: a systematic review and meta-analysis of safety in the mother, fetus and child. Addiction 2016;111:2115-28.
79. Noormohammadi A, Forinash A, Yancey A, et al. Buprenorphine versus methadone for opioid dependence in pregnancy. Ann Pharmacother 2016;50:666-72.
80. McCarthy JJ, Leamon MH, Finnegan LP, et al. Opioid dependence and pregnancy: minimizing stress on the fetal brain. Am J Obstet Gynecol 2017;216: 226-31.
81. Smyth BP, Barry J, Keenan E, et al. Lapse and relapse following inpatient treatment of opiate dependence. Ir Med J 2010;103:176-9.
82. Gossop M, Stewart D, Browne N, et al. Factors associated with abstinence, lapse or relapse to heroin use afer residential treatment: protective efect of coping responses. Addiction 2002;97:1259-67.
83. Chen T, Masson CL, Sorensen JL, et al. Residential treatment modifications: adjunctive services to accommodate clients on methadone. Am J Drug Alcohol Abuse 2009;35:91-4.
84. Greenberg B, Hall DH, Sorensen JL. Methadone maintenance therapy in residential therapeutic community settings: challenges and promise. J Psychoactive Drugs 2007;39:203-10.
85. Sorensen JL, Andrews S, Delucchi KL, et al. Methadone patients in the therapeutic community: a test of equivalency. Drug Alcohol Depend 2009;100:100-6.
86. Kampman K, Jarvis M. American Society of Addiction Medicine (ASAM) National Practice Guideline for the use of medications in the treatment of addiction involving opioid use. J Addict Med 2015;9:358-67.
87. Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence. Geneva: World Health Organization; 2009. Available: https://www.ncbi.nlm.nih.gov/books/NBK143185 (accessed 2017 June 27).
88. Weiss RD, Potter JS, Grifin ML, et al. Long-term outcomes from the National Drug Abuse Treatment Clinical Trials Network Prescription Opioid Addiction Treatment Study. Drug Alcohol Depend 2015;150:112-9.
89. Weiss RD, Potter JS, Fiellin DA, et al. Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence: a 2-phase randomized controlled trial. Arch Gen Psychiatry 2011;68:1238-46.
90. Fiellin DA, Schottenfeld RS, Cutter CJ, et al. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med 2014;174:1947-54.